Bartter syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
TayyabaAli (talk | contribs) No edit summary |
TayyabaAli (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
*Prostaglandin synthetase inhibitors suppress the production of prostaglandin. This corrects all the chemical features of the syndrome except the urinary loss of potassium.<ref name="pmid820194">{{cite journal| author=Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW | display-authors=etal| title=Bartter's syndrome: a disorder characterized by high urinary prostaglandins and | *Prostaglandin synthetase inhibitors suppress the production of prostaglandin. This corrects all the chemical features of the syndrome except the urinary loss of potassium.<ref name="pmid820194">{{cite journal| author=Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW | display-authors=etal| title=Bartter's syndrome: a disorder characterized by high urinary prostaglandins and dependence of hyperreninemia on prostaglandin synthesis. | journal=Am J Med | year= 1976 | volume= 61 | issue= 1 | pages= 43-51 | pmid=820194 | doi=10.1016/0002-9343(76)90029-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=820194 }} </ref> | ||
*[[Hypokalemia]] should be treated. [[Potassium chloride]] supplements are preferred salt because of the coexisting [[chloride]] deficiencies in these patients.<ref name="pmid26140272">{{cite journal| author=Al Shibli A, Narchi H| title=Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. | journal=World J Methodol | year= 2015 | volume= 5 | issue= 2 | pages= 55-61 | pmid=26140272 | doi=10.5662/wjm.v5.i2.55 | pmc=4482822 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26140272 }} </ref> | |||
While patients should be encouraged to include liberal amounts of sodium and potassium in their diet, potassium supplements are usually required, and [[spironolactone]] is also used to reduce potassium loss. [[Nonsteroidal antiinflammatory drugs]] (NSAIDs) can be used as well, and are particularly helpful in patients with neonatal Bartter's syndrome. [[ACE inhibitor|Angiotensin-converting enzyme (ACE) inhibitors]] can also be used. | While patients should be encouraged to include liberal amounts of sodium and potassium in their diet, potassium supplements are usually required, and [[spironolactone]] is also used to reduce potassium loss. [[Nonsteroidal antiinflammatory drugs]] (NSAIDs) can be used as well, and are particularly helpful in patients with neonatal Bartter's syndrome. [[ACE inhibitor|Angiotensin-converting enzyme (ACE) inhibitors]] can also be used. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 18:54, 4 August 2020
Main article: Bartter syndrome
|
Bartter syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Bartter syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Bartter syndrome medical therapy |
|
Risk calculators and risk factors for Bartter syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]
Overview
Medical Therapy
- Prostaglandin synthetase inhibitors suppress the production of prostaglandin. This corrects all the chemical features of the syndrome except the urinary loss of potassium.[1]
- Hypokalemia should be treated. Potassium chloride supplements are preferred salt because of the coexisting chloride deficiencies in these patients.[2]
While patients should be encouraged to include liberal amounts of sodium and potassium in their diet, potassium supplements are usually required, and spironolactone is also used to reduce potassium loss. Nonsteroidal antiinflammatory drugs (NSAIDs) can be used as well, and are particularly helpful in patients with neonatal Bartter's syndrome. Angiotensin-converting enzyme (ACE) inhibitors can also be used.
References
- ↑ Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW; et al. (1976). "Bartter's syndrome: a disorder characterized by high urinary prostaglandins and dependence of hyperreninemia on prostaglandin synthesis". Am J Med. 61 (1): 43–51. doi:10.1016/0002-9343(76)90029-2. PMID 820194.
- ↑ Al Shibli A, Narchi H (2015). "Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations". World J Methodol. 5 (2): 55–61. doi:10.5662/wjm.v5.i2.55. PMC 4482822. PMID 26140272.